Cell Therapy manufacturing facility
This Cell Therapy Launch and Manufacturing Facility has won the ‘Social Impact’ Category in ISPE’s 2025 Facility of the Year Awards.
Meeting critical unmet needs
Located at Bayer's Berkeley campus in California, this new facility signifies a major advancement in the production and commercialization of innovative cell therapies aimed at addressing critical unmet medical needs.
The circa 100,000 sq.ft. facility is designed for late-stage clinical manufacturing and commercial launches of cell therapies, creating readiness for first production runs.
It features flexible, modular space for cell culture, viral transduction, and automated filling, leveraging Bayer's expertise in regenerative medicines.
Category Winner
ISPE
Facility of the Year Awards 2025. Social Impact Category Winner
Sustainability
LEED
Certified to LEED v4 Platinum.
“Being part of the extraordinary team to deliver such a novel facility for Bayer, and more importantly for their patients, has been a very humbling experience."
Andrew Slusser
Director of Architecture, USA West
Advanced cell therapy production
Its cleanroom manufacturing suites are designed for NIH BMBL BSL-2 containment and dedicated to advancing autologous cell therapy production.
The 30,000 sq.ft. suites utilize concurrent multi-product manufacturing and viral or non-viral gene editing technologies to enhance cell functionality.
Designed to meet the highest sustainability standards, the facility has been certified to LEED v4 Platinum.
Related specialists
Automated allogeneic cell therapy process
Bayer is at the forefront of large-scale allogeneic cell therapies specifically designed to treat Parkinson's disease.
The company is also pioneering cell manipulation and automated liquid handling systems and leveraging single use materials.
PM Group supported the project through architectural and engineering services from the initial feasibility through the construction and commissioning of the facility.
Significant societal impact
Bayer’s initiative represents a significant advancement in the production of allogeneic cell therapies, aimed at delivering high-quality, consistent treatments. This facility is expected to significantly improve the lives of patients by facilitating development of innovative therapies.
